Dosing
-
Publication: CARMELINA Elderly Subgroup Analysis [1]
Review the long-term safety profile of Trajenta® among age groups.
-
Publication: CAROLINA Asian Subgroup Analysis [2]
Review the long-term safety profile of Trajenta® in Asian patients.
-
-
10 Years of Simplicity
Browse through an interactive infographic showcasing the clinical development and significant accomplishments for Trajenta®.
Trajenta®(linagliptin)
One Dose, Once Daily. Always.*,3
Proportions of medication excreted via the kidney3-7
Lowest Kidney Excretion.3
Unlike most DPP4i, Trajenta® is primarily excreted via a non-kidney route.3-7 In fact, only about 5% of Trajenta® is excreted via kidneys. In contrast, for each of the other globally-available DPP4i, 75% or more of the drug is excreted via kidneys. As a result, dose adjustment is required for each of these other DPP4i in patients with kidney impairment and/or drug related kidney monitoring.4-7 In contrast, for Trajenta®, there is no need for additional drug-related kidney function monitoring and no dose adjustment required in patients with kidney impairment.3 One Dose, always. Simple. Trajenta®.
Most Convenient Dosing Schedule.3-7
Trajenta® is the only approved DPP4i that does not require dose reduction based on kidney function.3-7 As kidney function declines for diabetes patients, it has to be monitored for patients taking each of the other DPP4i, but not Trajenta®. As patients enter moderate or severe kidney impairment, or end stage kidney disease, the dose of each other DPP4i has to be adjusted or in some cases discontinued. Not with Trajenta®. One dose, always. Simplicity.
Required DPP4i dose with declining kidney function, as defined by SmPC
Footnotes
BID: twice daily; BMI: body mass index; CrCl: creatinine clearance; DPP4i: dipeptidyl peptidase-4 inhibitor; ESRD: end stage renal disease; GFR: glomerular filtration rate; KI: kidney impairment; QD: once daily; T2D: type 2 diabetes
* Indicated for use in adult patients. Trajenta® is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.
† Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.
‡ Combination therapies studied with linagliptin were: Linagliptin as add-on to metformin therapy; Linagliptin as add-on to a combination of metformin and sulphonylurea therapy; Linagliptin as add-on to a combination of metformin and empagliflozin; Linagliptin as add-on to insulin therapy.
§ No dose adjustment is necessary based on age.
References
- 1.Cooper M, et al. Diabetes Obes Metab. 2020; 1–12.
- 2.Kadowaki T, et al. Diabetol Int. 2020. doi.org/10.1007/s13340-020-00447-5.
- 3.Trajenta® EMA Summary of Product Characteristics, October 2019.
- 4.Januvia® EMA Summary of Product Characteristics.
- 5.Galvus® EMA Summary of Product Characteristics.
- 6.Vipidia® EMA Summary of Product Characteristics.
- 7.Onglyza® EMA Summary of Product Characteristics.